On the stock market since 1992, it operates in the world of health and science. It has 7,600 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The gap is $648.5M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
It pays out $1.04 per share each year — regular cash for whoever holds the stock.
The stock trades 10% above the average analyst price target.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, PDCO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PDCO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.